Parameter | Intention to treat analysis | Per protocol analysis | ||||
---|---|---|---|---|---|---|
Carb/TAX n = 22 | CDDP/5FU n = 25 | p-value | Carb/TAX n = 18 | CDDP/5FU n = 23 | p-value | |
Median Age (IQR) | 68 (62–74) | 66 (62–69) | 0.149 | 68 (62–72) | 66 (58–69) | 0.337 |
Male | 15 (68%) | 21 (84%) | 0.303 | 13 (72%) | 19 (83%) | 0.471 |
T-stage | 0.247 | 0.265 | ||||
uT1 | 1 (5%) | 0 (0%) | 1 (6%) | 0 (0%) | ||
uT2 | 4 (18%) | 2 (8%) | 4 (22%) | 2 (9%) | ||
uT3 | 16 (73%) | 27 (72%) | 12 (67%) | 17 (74%) | ||
uT4 | 1 (5%) | 5 (20%) | 1 (6%) | 4 (17%) | ||
uN+ | 21 (95%) | 23 (92%) | 1.000 | 17 (94%) | 21 (91%) | 1.000 |
cM0 | 22 (100%) | 24 (96%) | 1.000 | 18 (100%) | 22 (96%) | 1.000 |
Grading | 0.756 | 0.515 | ||||
G2 | 11 (61%) | 13 (52%) | 9 (64%) | 12 (52%) | ||
G3 | 7 (39%) | 12 (48%) | 5 (36%) | 11 (48%) | ||
Median tumor extension (cm) (IQR) | 5 (3–7) | 5 (5–7) | 0.216 | 5 (3–6) | 5 (5–6) | 0.108 |
Median radiation dose (Gy) (IQR) | 59.4 (55.8–59.4) | 54.0 (54.0–54.0) | < 0.001 | 59.4 (54.0–59.4) | 54.0 (54.0–54.0) | < 0.001 |
Median daily radiation dose (Gy) (IQR) | 1.8 (1.8–1.8) | 1.8 (1.8–1.8) | 0.253 | 1.8 (1.8–1.8) | 1.8 (1.8–2.0) | 0.429 |